SEARCH

SEARCH BY CITATION

References

  • 1
    Anonymous. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:122532.
  • 2
    Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994;30:359.
  • 3
    Illi S, Von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004;113:92531.
  • 4
    Williams HC, Strachan DP. The natural history of childhood eczema: observations from the British 1958 birth cohort study. Br J Dermatol 1998;139:8349.
  • 5
    Ozkaya E. Adult-onset atopic dermatitis. J Am Acad Dermatol 2005;52:57982.
  • 6
    Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med 2005;83:68292.
  • 7
    Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson D et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 2000;26:4703.
  • 8
    Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001;27:3723.
  • 9
    Bradley M, Soderhall C, Luthman H, Wahlgren CF, Kockum I, Nordenskjold M. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet 2002;11:153948.
  • 10
    Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, Tan Q et al. Atopic dermatitis—a total genome-scan for susceptibility genes. Acta Derm Venereol 2004;84:34652.
  • 11
    Novak N, Kruse S, Potreck J, Weidinger S, Fimmers R, Bieber T. Single nucleotide polymorphisms of the IL18 gene are associated with atopic eczema. J Allergy Clin Immunol 2005;115:82833.
  • 12
    Weidinger S, Klopp N, Rümmler L, Wagenpfeil S, Novak N, Baurecht HJ et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 2005;116:17784.
  • 13
    Weidinger S, Rümmler L, Klopp N, Wagenpfeil S, Baurecht HJ, Fischer G et al. Association study of mast cell chymase polymorphisms with atopy. Allergy 2005;60:125661.
  • 14
    Laubereau B, Brockow I, Zirngibl A, Koletzko S, Gruebl A, Von Berg A et al. Effect of breast-feeding on the development of atopic dermatitis during the first 3 years of life – results from the GINI-birth cohort study. J Pediatr 2004;144:6027.
  • 15
    Schafer T. [Prevention of atopic eczema. Evidence based guidelines]. Hautarzt 2005;56:23240
  • 16
    Capristo C, Romei I, Boner AL. Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: avoidance of indoor allergens. Allergy 2004;59(Suppl. 78):5360.
  • 17
    Purvis DJ, Thompson JM, Clark PM, Robinson E, Black PN, Wild CJ et al. Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age. Br J Dermatol 2005;152:7429.
  • 18
    Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 1999;104:12804.
  • 19
    Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998;101:e8.
  • 20
    Warner JOETAC Study Group. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol 2001;108:92937.
  • 21
    Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis—a prospective follow-up to 7 years of age. Allergy 2000;55:2405.
  • 22
    Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998;101:161422.
  • 23
    Lack G, Fox D, Northstone K, Golding J, Avon Longitudinal Study of Parents and Children Study Team. Factors associated with the development of peanut allergy in childhood. N Eng J Med 2003;348:97785.
  • 24
    Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112(suppl):S12839.
  • 25
    Leung DYM, Bhan AK, Schneeberger EE, Geha RS. Characterization of the mononuclear cell infiltrate in atopic dermatitis using monoclonal antibodies. J Allergy Clin Immunol 1983;71:4756.
  • 26
    Novak N, Kraft S, Bieber T. IgE receptors. Curr Opin Immunol 2001;13:7216.
  • 27
    Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113:6517.
  • 28
    Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic dermatitis. J Clin Invest 1994;94:8706.
  • 29
    Bratton DL, Hamid Q, Boguniewicz M, Doherty DE, Kailey JM, Leung DY. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. J Clin Invest 1995;95:2118.
  • 30
    Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P et al. Polarized in vivo expression of IL-11 and Il-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003;111:87581.
  • 31
    Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A et al. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis. J Allergy Clin Immunol 2000;105:10027.
  • 32
    Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004;113:33440.
  • 33
    Echigo T, Hasegawa M, Shimada Y, Takehara K, Sato S. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation. J Allergy Clin Immunol 2004;113:9408.
  • 34
    Klunker S, Trautmann A, Akdis M, Verhagen J, Schmid-Grendelmeier P, Blaser K et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-gamma-inducible protein 10, monokine induced by IFN-gamma, and IFN-gamma-inducible alpha-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J Immunol 2003;171:107884.
  • 35
    Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:25262.
  • 36
    Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wuthrich B. Epidemiology, clinical features, and immunology of the ‘‘intrinsic’’ (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001;56:8419.
  • 37
    Scheynius A, Johansson C, Buentke E, Zagari A, Linder MT. Atopic eczema/dermatitis syndrome and Malassezia. Int Arch Allergy Immunol 2002;127:1619.
  • 38
    Novak N, Allam JP, Bieber T. Allergic hyperreactivity to microbial components: a trigger factor of ‘‘intrinsic’’ atopic dermatitis? J Allergy Clin Immunol 2003;112:2156.
  • 39
    Kerschenlohr K, Decard S, Darsow U, Ollert M, Wollenberg A. Clinical and immunologic reactivity to aeroallergens in ‘‘intrinsic’’ atopic dermatitis patients. J Allergy Clin Immunol 2003;111:1957.
  • 40
    Novembre E, Cianferoni A, Lombardi E, Bernardini R, Pucci N, Vierucci A. Natural history of ‘‘intrinsic’’ atopic dermatitis. Allergy 2001;56:4523.
  • 41
    Novak N, Tepel C, Koch S, Brix K, Bieber T, Kraft S. Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors. J Clin Invest 2003;111:104756.
  • 42
    Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003;48:3528.
  • 43
    Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 2002;119:4339.
  • 44
    Rippke F, Schreiner V, Doering T, Maibach HI. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus aureus. Am J Clin Dermatol 2004;5:21723.
  • 45
    Vasilopoulos Y, Cork MJ, Murphy R, Williams HC, Robinson DA, Duff GW et al. Genetic association between an AACC insertion in the 3’UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol 2004;123:626.
  • 46
    Baud O, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001;344:175862.
  • 47
    Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of Th1 and Th2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999;103:110311.
  • 48
    Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A. Pimecrolimus leads to an apoptosis-induced depletion of T cells, but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005;115:127683.
  • 49
    Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001;117:97783.
  • 50
    Akdis M, Trautmann A, Klunker S, Daigle I, Kucuksezer UC, Deglmann W et al. T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 2003;17:102635.
  • 51
    Akdis CA, Blaser K, Akdis M. Apoptosis in tissue inflammation and allergic disease. Curr Opin Immunol 2004;16:71723.
  • 52
    Umetsu DT, Akbari O, Dekruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol 2003;112:4807.
  • 53
    Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:156775.
  • 54
    Carneiro R, Reefer A, Wilson B, Hammer J, Platts-Mills J, Custis N et al. T cell epitope-specific defects in the immune response to cat allergen in patients with atopic dermatitis. J Invest Dermatol 2004;122:92736.
  • 55
    Lin W, Truong N, Grossman WJ, Haribhai D, Williams CB, Wang J et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol 2005;116:110615.
  • 56
    Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004;113:75663.
  • 57
    Novak N, Valenta R, Bohle B, Laffer S, Haberstok J, Kraft S et al. Fcepsilon RI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell-like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol 2004;113:94957.
  • 58
    Wollenberg A, Wagner M, Gunther S, Towarowski A, Tuma E, Moderer M et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:1096102.
  • 59
    Novak N, Allam JP, Hagemann T, Jenneck C, Laffer S, Valenta R et al. Characterization of FcepsilonRI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2004;114:36470.
  • 60
    Sayama K, Komatsuzawa H, Yamasaki K, Shirakata Y, Hanakawa Y, Ouhara K et al. New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of β-defensins, LL37, and TLR2. Eur J Immunol 2005;35:188695.
  • 61
    Giustizieri ML, Mascia F, Frezzolini A, De Pita O, Chinni LM, Giannetti A et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001;107:8717.
  • 62
    Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 2005;202:5419.
  • 63
    Trautmann A, Akdis M, Kleeman D, Altznauer F, Simon H-U, Graeve T et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest 2000;106:2535.
  • 64
    Pastore S, Corinti S, La Placa M, Didona B, Girolomoni G. Interferon-gamma promotes exaggerated cytokine production in keratinocytes cultured from patients with atopic dermatitis. J Allergy Clin Immunol 1998;101:53844.
  • 65
    Trautmann A, Altznauer F, Akdis M, Simon H-U, Disch R, Bröcker E-B et al. The differential fate of cadherins during T cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J Invest Derm 2001;117:92734.
  • 66
    Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Bröcker E-B, Blaser K et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J Allergy Clin Immunol 2001;108:83946.
  • 67
    Kapp A. The role of eosinophils in the pathogenesis of atopic dermatitis – eosinophil granule proteins as markers of disease activity. Allergy 1993;48:15.
  • 68
    Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004;59:56170.
  • 69
    Schmid-Ott G, Jaeger B, Adamek C, Koch H, Lamprecht F, Kapp A et al. Levels of circulating CD8+ T-lymphocytes, natural killer cells and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001;107:1717.
  • 70
    Wedi B, Raap U, Lewrick H, Kapp A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997;100:53643.
  • 71
    Grewe M, Czech W, Morita A, Werfel T, Klammer M, Kapp A et al. Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J Immunol 1998;161:41520.
  • 72
    Raap U, Goltz C, Deneka N, Bruder M, Renz H, Kapp A et al. Brain-derived neurotrophic factor is increased in atopic eczema and modulates eosinophil functions compared with that seen in nonatopic subjects. J Allergy Clin Immunol 2005;115:126875.
  • 73
    Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:15160.
  • 74
    Leo HL, Bender BG, Leung SB, Tran ZV, Leung DY. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. J Allergy Clin Immunol 2004;114:69193.
  • 75
    Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999;135:152225.
  • 76
    Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495504.
  • 77
    Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999;140:111421.
  • 78
    Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:75260.
  • 79
    Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005;516:1801.
  • 80
    Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewcz M, Yao L et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 2006;117:41825.
  • 81
    Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:4117.
  • 82
    Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002;147:719.
  • 83
    Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004;113:80519.
  • 84
    Werfel T, Breuer K. Role of food allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol 2004;4:37985.
  • 85
    Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wuthrich B et al. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy 2004;59:131825.
  • 86
    Leung DY. Infection in atopic dermatitis. Curr Opin Pediatr 2003;15:399404.
  • 87
    Leung DYM, Harbeck H, Bina P, Reiser RF, Yang E, Norris AD et al. Presence of IgE antibodies to staphylococcal enterotoxins on the skin of patients with atopic dermatitis: evidence for a new group of allergens. J Clin Invest 1993;92:137480.
  • 88
    Hauk PJ, Leung DYM. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis? J Allergy Clin Immunol 2001;107:3912.
  • 89
    Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:115160.
  • 90
    Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003;171:32629.
  • 91
    Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006;117:83641.
  • 92
    Plaut M, Tinkle SS. Risks of smallpox vaccination: 200 years after Jenner. J Allergy Clin Immunol 2003;112:6835.
  • 93
    Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy 1999;54:4139.
  • 94
    Scalabrin DM, Bavbek S, Perzanowski MS, Wilson BB, Platts-Mills TA, Wheatley LM et al. Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 1999;104:12739.
  • 95
    Schmid-Grendelmeier P, Scheynius A, Crameri R. The role of sensitization to Malassezia sympodialis in atopic eczema. Chem Immunol Allergy 2006;91:98109.
  • 96
    Mothes N, Niggemann B, Jenneck C, Hagemann T, Weidinger S, Bieber T et al. The cradle of IgE hyperreactivity in atopic eczema lies in infancy. J Allergy Clin Immunol 2005;116:7069.
  • 97
    Natter S, Seiberler S, Hufnagl P, Binder BR, Hirschl AM, Ring J et al. Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 1998;12:155969.
  • 98
    Valenta R, Seiberler S, Natter S, Mahler V, Mossabeb R, Ring J et al. Autoallergy – a pathogenetic factor in atopic dermatitis. J Allergy Clin Immunol 2000;105:4327.
  • 99
    Schmid-Grendelmeier P, Fluckiger S, Disch R, Trautmann A, Wuthrich B, Blaser K et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 2005;115:106875.
  • 100
    Hanifin JM, Rajka G. Diagnostic features of atopic eczema. Acta Dermatol Venereol (Stockh) 1980;92:447.
  • 101
    Johnke H, Vach W, Norberg LA, Bindslev-Jensen C, Host A, Andersen KE. A comparison between criteria for diagnosing atopic eczema in infants. Br J Dermatol 2005;153:3528.
  • 102
    Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005;116:94959.
  • 103
    Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, Blanco C, Ebner C, Hourihane J et al. Standardization of food challenges in patients with immediate reactions to foods—position paper from the European Academy of Allergology and Clinical Immunology. Allergy 2004;59:6907.
  • 104
    Breuer K, Heratizadeh A, Wulf A, Baumann U, Constien A, Tetau D et al. Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy 2004;34:81724.
  • 105
    Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001;107:8916.
  • 106
    Osterballe M, Bindslev-Jensen C. Threshold levels in food challenge and specific IgE in patients with egg allergy: is there a relationship? J Allergy Clin Immunol 2003;112:196201.
  • 107
    Celik-Bilgili S, Mehl A, Verstege A, Staden U, Nocon M, Beyer K et al. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. Clin Exp Allergy 2005;35:26873.
  • 108
    Turjanmaa K. The role of atopy patch tests in the diagnosis of allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol 2005;5:4258.
  • 109
    Mitchell EB, Crow J, Chapman MD, Jouhal SS, Pope FM, Platts-Mills TA. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982;1:12730.
  • 110
    Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996;347:158.
  • 111
    Platts-Mills TA, Mitchell EB, Rowntree S, Chapman MD, Wilkins SR. The role of dust mite allergens in atopic dermatitis. Clin Exp Dermatol 1983;8:23347.
  • 112
    Morren MA, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: triggering factors. J Am Acad Dermatol 1994;31:46773.
  • 113
    Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther 2004;17:2634.
  • 114
    Sampson HA. Food allergy – accurately identifying clinical reactivity. Allergy 2005;60(Suppl. 79):1924.
  • 115
    Seidenari S, Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 1996;75:42933.
  • 116
    Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003;4:77188.
  • 117
    McHenry PM, Williams HC, Bingham EA. Management of atopic eczema: Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London. BMJ 1995;310:8437.
  • 118
    Ellis C, Luger Ton behalf of the ICCAD II Faculty. International consensus conference on atopic dermatitis II (ICCAD II*): clinical update and current treatment strategies. Br J Dermatol 2003;148:310.
  • 119
    Rudolph R, Kownatzki E. Corneometric, sebumetric and TEWL measurements following the cleaning of atopic skin with a urea emulsion versus a detergent cleanser. Contact Dermatitis 2004;50:3548.
  • 120
    Darsow U, Lubbe J, Taieb A, Seidenari S, Wollenberg A, Calza AM et al. Position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:28695.
  • 121
    Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association ‘‘Administrative Regulations for Evidence-Based Clinical Practice Guidelines’’. J Am Acad Dermatol 2004;50:391404.
  • 122
    Korting HC, Kerscher MJ, Schafer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992;27:8792.
  • 123
    Kerscher MJ, Hart H, Korting HC, Stalleicken D. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995;33:1879.
  • 124
    Thomas KS, Armstrong S, Avery A, Po AL, O'Neill C, Young S et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2003;30:768.
  • 125
    Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326:1367.
  • 126
    Stalder JF, Fleury M, Sourisse M, Rostin M, Pheline F, Litoux P. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994;131:53640.
  • 127
    Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992;27:2934.
  • 128
    Ainley-Walker PF, Patel L, David TJ. Side to side comparison of topical treatment in atopic dermatitis. Arch Dis Child 1998;79:14952.
  • 129
    Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005;211:17487.
  • 130
    Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
  • 131
    Harper J, Green A, Scott G, Gruendl E, Dorobek B, Cardno B et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001;144:7817.
  • 132
    Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330:516.
  • 133
    Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:78894.
  • 134
    Paul C, Cork M, Rossi AB, Papp KA, Barbier N, De Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006;117:11828.
  • 135
    Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005;6:6577.
  • 136
    Kempers S, Boguniewicz M, Carter E, Jarratt M, Pariser D, Stewart D et al. A randomized inverstigator-blinded study comparing pimecrolimus cream 1% with tacrolimus 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 2004;51:51525.
  • 137
    Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M et al. The new topical ascomycin derivate SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:50713.
  • 138
    Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003;49:198205.
  • 139
    Elidel [package insert]. Basel, Switzerland: Novartis Pharmaceuticals Corp.; 2006.
  • 140
    Protopic [package insert. Deerfield, Ill: Astellas Pharma Manufacturing Inc.; 2006.
  • 141
    Mallon E, Powell S, Bridgman A. ‘‘Wet-wrap’’ dressings for the treatment of atopic eczema in the community. J Dermatolog Treat 1994;5:978.
  • 142
    Oranje AP, Wolkerstorfer A, De Waard-van der Spek FB. Treatment of erythrodermic atopic dermatitis with ‘‘wet-wrap’’ fluticasone propionate 0.05% cream/emollient 1:1 dressings. J Dermatolog Treat 1999;10:734.
  • 143
    Foelster-Holst R, Nagel F, Zoellner P, Spaeth D. Efficacy of crisis intervention treatment with topical corticosteroid prednicarbat with and without partial wet-wrap dressing in atopic dermatitis. Dermatology 2006;212:669.
  • 144
    Boguniewicz M, Nicol N. Conventional therapy. Immunol Allergy Clinics N Am 2002;22:10724.
  • 145
    Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001;56:103441.
  • 146
    Breuer K, HAussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002;147:5561.
  • 147
    Sporik R, Kemp AS. Topical triclosan treatment of atopic dermatitis. J Allergy Clin Immunol 1997;99:861.
  • 148
    Bhargava HN, Leonhard PA. Triclosan: application and safety. Am J Infect Control 1996;24:20918.
  • 149
    Gauger A, Mempel M, Schekatz A, Schafer T, Ring J, Abeck D. Silver-coated textiles reduce Staphylococcus aureus colonization in patients with atopic eczema. Dermatology 2003;207:1521.
  • 150
    Ricci G, Patrizi A, Bendandi B, Menna G, Varotti E, Masi M. Clinical effectiveness of a silk fabric in the treatment of atopic dermatitis. Br J Dermatol 2004;150:12731.
  • 151
    Leyden JJ, Kligman AM. The case for steroid-antibiotic combination. Br J Dermatol 1977;96:17987.
  • 152
    Jappe U, Schnuch A, Uter W. Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995–1999. Br J Dermatol 2003;149:8793.
  • 153
    Abeck D, Mempel M. Staphylococcus aureus colonisation in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998;139:1316.
  • 154
    Verbist I. The antimicrobial activity of fucidic acid. J Antimicrob Chemother 1990;25(Suppl. B):15.
  • 155
    Ravenscroft JC, Layton A, Barnham M. Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin Exp Dermatol 2000;25:32730.
  • 156
    Peeters KABM, Mascini EM, Sanders CJG. Resistance of Staphylococcus aureus to fusidic acid. Int J Dermatol 2004;43:2357.
  • 157
    Ravenscroft JC, Layton AM, Eady EA, Murtagh MS, Coates P, Walker M et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003;148:10107.
  • 158
    Lubbe J. Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003;4:64154.
  • 159
    Hoeger PH. Antimicrobial susceptibility of skin-colonizing S. aureus strains in children with atopic dermatitis. Pediatr Allergy Immunol 2004;15:4747.
  • 160
    Boguniewicz M, Sampson H, Harbeck R, Leung DYM. Effects of cefuroxime axetil on S. aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001;108:6512.
  • 161
    Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001;56:5127.
  • 162
    Baeck O, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Derm Venereol 2001;15:348.
  • 163
    Nikkels AF, Piérard GE. Framing the future of antifungals in atopic dermatitis. Dermatology 2003;206:398400.
  • 164
    Aylett SE, Atherton DJ, Preece MA. The treatment of difficult atopic dermatitis in childhood with oral beclomethasone dipropionate. Acta Derm Venereol Suppl 1992;176:1235.
  • 165
    Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:13740.
  • 166
    Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996;34:101621.
  • 167
    Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996;135(Suppl. 48):214.
  • 168
    Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997;136:7681.
  • 169
    Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 2003;21:22540.
  • 170
    Anstey AV, Wakelin S, Reynolds NJ. British Association of Dermatologists Therapy, Guidelines and Audit Subcommittee. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 2004;151:112332.
  • 171
    Tan BB, Lear JT, Gwakrdger DJ, English JSC. Azathioprine in dermatology: a survey of current practice in the UK. Br J Dermatol 1997;136:3515.
  • 172
    Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001;26:36975.
  • 173
    Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002;147:32430.
  • 174
    Lear JT, English JSC, Jones P, Smith AG. Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 1996;35:6423.
  • 175
    Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:1937.
  • 176
    Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. British Association of Dermatologists. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002;147:21421.
  • 177
    Wahlgren C-F, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990;122:54551.
  • 178
    Diepgen TL. Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002;13:27886.
  • 179
    Scheinfeld NS, Tutrone WD, Weinberg JM, DeLeo VA. Phototherapy of atopic dermatitis. Clin Dermatol 2003;21:24148.
  • 180
    Abeck D, Schmidt T, Fesq H, Strom K, Mempel M, Brockow K et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000;42:2547.
  • 181
    Krutmann J, Diepgen TL, Luger TA, Grabbe S, Meffert H, Sonnichsen N et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998;38:58993.
  • 182
    Reynolds NJ, Franklin V, Gray JC, Diffey BL, Farr PM. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001;357:20126.
  • 183
    Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am J Clin Dermatol 2004;5:28194.
  • 184
    Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose–response study. Allergy 2006;61:2025.
  • 185
    Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52:5226.
  • 186
    Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005;53:3589.
  • 187
    Dimitroff CJ, Kupper TS, Sackstein R. Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen. J Clin Invest 2004;112:100818.
  • 188
    Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. Br J Dermatol 2002;146:4329.
  • 189
    McSkimming J, Gleeson L, Sinclair M. A pilot study of a support group for parents of children with eczema. Australas J Dermatol 1984;25:811.
  • 190
    Koblenzer CS, Koblenzer PJ. Chronic intractable atopic eczema. Arch Dermatol 1988;124:16737.
  • 191
    Broberg A, Kalimo K, Lindblad B, Swanbeck G. Parental education in the treatment of childhood atopic eczema. Acta Derm Venereol 1990;70:4959.
  • 192
    Staab D, Ruden U, Kehrt R, Wahn U. The impact of childhood atopic dermatitis on quality of life of family. Dematol Psychosom 2000;1:1738.
  • 193
    Staab D, Diepgen T, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J et al. Age-related, structured education programmes improve the management of atopic dermatitis in children and adolescents: results of the German Atopic Dermatitis Intervention Study (GADIS). BMJ 2006;332:9338.
  • 194
    Halken S, Hansen KS, Jacobsen HP, Estmann A, Faelling AE, Hansen LG et al. Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention: a prospective, randomized study. Pediatr Allergy Immunol 2000;11:14961.
  • 195
    Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004;15(Suppl. 16):45,9–32.
  • 196
    Mimouni Bloch A, Mimouni D, Mimouni M, Gdalevich M. Does breastfeeding protect against allergic rhinitis during childhood? A meta-analysis of prospective studies. Acta Paediatr 2002;91:2759.
  • 197
    Muraro A, Dreborg S, Halken S, Host A, Niggemann B, Aalberse R et al. Dietary prevention of allergic diseases in infants and small children. Part III: critical review of published peer-reviewed observational and interventional studies and final recommendations. Pediatr Allergy Immunol 2004;15:291307.
  • 198
    Von Berg A, Koletzko S, Grubl A, Filipiak-Pittroff B, Wichmann HE, Bauer CP et al. The effect of hydrolyzed cow's milk formula for allergy prevention in the first year of life: the German Infant Nutritional Intervention Study, a randomized double-blind trial. J Allergy Clin Immunol 2003;111:53340.
  • 199
    Muraro A, Dreborg S, Halken S, Host A, Niggemann B, Aalberse R et al. Dietary prevention of allergic diseases in infants and small children. Part II. Evaluation of methods in allergy prevention studies and sensitization markers. Definitions and diagnostic criteria of allergic diseases. Pediatr Allergy Immunol 2004;15:196205.
  • 200
    Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:160410.